Navigation Links
Oncobiologics and inVentiv Health Form Strategic Partnership around Biosimilars
Date:8/6/2013

CRANBURY, N.J., Aug. 6, 2013 /PRNewswire/ -- Oncobiologics, Inc. and inVentiv Health today announced a broad strategic partnership around clinical development for all assets in Oncobiologic's pipeline.  The scope of the partnership is global and will initially focus on biosimilar assets, and could be expanded to include innovative molecules.  Through the partnership, inVentiv Health will provide leadership and execution for clinical studies, as well as the corresponding bioanalytical support for those trials.  As the assets are commercialized, the partnership will be broadened to include inVentiv's significant commercialization capabilities in select countries.  This will position Oncobiologics attractively in seeking future commercial partners.

The current biosimilar assets include generic versions of Humira®, Rituxan®, Avastin®, Herceptin® and Erbitux®. These biologics are the most popular therapies in the world for their respective cancer and immune-disease indications, representing annual global revenue of more than $40 billion.

"After an exhaustive global review of potential partners, we selected the broad-scale inVentiv platform as an important differentiator for our program as this partnership spans both clinical and bioanalytical development as well as commercialization of our biosimilar assets.  inVentiv is able to take the scope of these agreements to a much broader level by working across the full development life cycle of each biosimilar and innovator product while preparing for a successful market launch. With their willingness to share in the risk/reward of our development programs, our firms are a perfect fit, both technically and culturally," said Oncobiologics Founder & CEO, Pankaj Mohan, Ph.D.

Ray Hill, President, inVentiv Health Clinical added, "We are thrilled to partner with Oncobiologics and to be a part of their highly capable biosimilars consortium.  With their recent global partnering successes, we look forward to helping Oncobiologics bring their biosimilar assets through clinical trials and into the marketplace. By joining their fully-integrated CMC capabilities with inVentiv's broad clinical and commercial expertise, we are creating a venture that is truly greater than the sum of its parts."

About Oncobiologics, Inc.
Oncobiologics is a privately-held biopharmaceutical company that has developed a pipeline of biosimilars and is developing next generation biotherapeutics focused on clinically validated targets in the therapeutic areas of oncology, immuno-oncology, and immunology. Formed by a team of leading industry experts from firms such as Eli Lilly, Bristol-Myers Squibb, Amgen, Genentech, Merck and Pfizer, Oncobiologics operates from a state-of-the-art 30,000 sq. ft. R&D facility in Cranbury, NJ. For more information, please visit www.oncobiologics.com

About inVentiv Health Clinical
inVentiv Health Clinical is a leading provider of global drug development services to pharmaceutical, biotechnology, generic drug, and medical device companies, offering therapeutically specialized capabilities for Phase I-IV clinical development, bioanalytical services, and strategic resourcing from a single clinical professional to an entire functional team.  With 7,000 passionate employees operating in more than 70 countries, inVentiv Health Clinical works to accelerate high quality drug development programs of all sizes around the world.  http://www.inventivhealthclinical.comContact:Rick GregoryDirector of Marketing & CommunicationsOncobiologics, Inc.rickgregory@oncobiologics.com


'/>"/>
SOURCE Oncobiologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Huahai and Oncobiologics Create Broad Biosimilars Partnership
2. Oncobiologics and Boston Oncology Team Up to Deliver Biosimilar Therapies for Cancer and Immune Disease to Middle East and North African Markets
3. inVentiv Health Partners With Medikly To Speed Clinical Trials By Accelerating The Recruitment Of Investigators
4. inVentiv Health Forms Strategic Alliance With Bell Medical Solutions, One Of Japans Top Clinical Research Organizations
5. PharmaNet/i3 Renamed inVentiv Health Clinical
6. inVentiv Health Strengthens Clinical Leadership Team
7. inVentiv Medical Management Forms Partnership with Vital Decisions
8. Frost & Sullivan Analyzes Emerging Opportunities for Stakeholders in the Transforming Healthcare Industry
9. Human Circuit Recognized as Industry Leader in Commercial Integrator Magazines Business Series as a Top 5 Healthcare Market Media Integrator for 2013
10. The Center for Ultrasound Research and Education (CURE) Receives Institutional Accreditation from the Accrediting Bureau of Health Education Schools
11. Indonesias Healthcare Reforms Create Opportunities But Also Present New Market Access Hurdles for the Multinational Pharmaceutical Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
Breaking Medicine News(10 mins):